Session » Spondyloarthritis Including PsA – Treatment Poster III: PsA

Date: Monday, November 14, 2022

Time: 1:00PM-3:00PM

Meeting: ACR Convergence 2022

1:00PM-3:00PM: Abstract Number: 2118

Achieving Increasingly Stringent Clinical Disease Control Criteria Is Associated with Greater Improvements in Patient-Centric Measures of Physical Function and Pain in Patients with Active PsA: 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies

1:00PM-3:00PM: Abstract Number: 2148

Analysis of Serum Proteomics Data Identifies Beta-Defensin 2 as a Predictive Biomarker of Clinical Response to IL-17 Blockade in Psoriatic Arthritis

1:00PM-3:00PM: Abstract Number: 2130

Apremilast in Bio-Naïve Patients with Early Psoriatic Arthritis: A National, Real-Life, Multicenter, Non-Interventional, Prospective, 52-week Cohort Study

1:00PM-3:00PM: Abstract Number: 2116

Assessment of the Ultrasound and Clinical Response to Apremilast Using a Joint-periarticular-nail Ultrasound Index and Clinical Evaluation in Patients with Active Psoriatic Arthritis

1:00PM-3:00PM: Abstract Number: 2133

Baseline Biomarkers Predict Better Responses to Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis

1:00PM-3:00PM: Abstract Number: 2117

Bimekizumab Improvements in Efficacy on Disease Activity Assessed via Composite Endpoints in Biologic DMARD-naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Phase 3 Randomized, Placebo-Controlled Studies

1:00PM-3:00PM: Abstract Number: 2122

Bimekizumab Treatment Improves Health-Related Quality of Life in Biologic DMARD-Naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies

1:00PM-3:00PM: Abstract Number: 2119

Bimekizumab Treatment Results in Improvements in Fatigue and Pain in Biologic DMARD-Naïve or TNFi-IR Patients with Active Psoriatic Arthritis: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies

1:00PM-3:00PM: Abstract Number: 2108

Changes in Serum Cytokines by Week 24 Correlate with Long-Term Efficacy of Guselkumab Through Two Years in Bio-Naïve Adults with PsA

1:00PM-3:00PM: Abstract Number: 2128

Consistent Long-Term Guselkumab Efficacy Across Psoriatic Arthritis Domains Irrespective of Baseline Patient Characteristics

1:00PM-3:00PM: Abstract Number: 2147

Cumulative Dose and Exposure Time to Methotrexate Were Not Shown to Be Predictors of Hepatic Fibrosis by Elastography – A Monocentric Cohort Study

1:00PM-3:00PM: Abstract Number: 2149

Cycling versus Swapping Strategies in Psoriatic Arthritis: Results from the Rheumatic Diseases Portuguese Register

1:00PM-3:00PM: Abstract Number: 2150

Cycling vs Swapping Strategies with TNFi and IL-17i in Psoriatic Arthritis: An Observational Retrospective Monocentric Study

1:00PM-3:00PM: Abstract Number: 2152

Depression and Other Neurological Disorders Are Associated with Biologic DMARD Failure in Psoriatic Arthritis

1:00PM-3:00PM: Abstract Number: 2134

Deucravacitinib Long-term Efficacy and Safety in Plaque Psoriasis: 2-Year Results from the Phase 3 POETYK PSO Program

1:00PM-3:00PM: Abstract Number: 2136

Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in Psoriatic Arthritis: Achievement of Minimal Disease Activity and Its Components

1:00PM-3:00PM: Abstract Number: 2109

Domains Contributing to Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis Receiving Golimumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study

1:00PM-3:00PM: Abstract Number: 2114

Early Clinical Improvement as Predictor of Long-term Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Guselkumab: Post Hoc Analysis Through 2 Years of a Phase 3 Study

1:00PM-3:00PM: Abstract Number: 2115

Early Skin and Early Enthesitis Responses in Psoriatic Arthritis Patients Treated with Guselkumab Associate with Long-term Response: Post Hoc Analysis Through 2 Years of a Phase 3 Study

1:00PM-3:00PM: Abstract Number: 2143

Effect of Upadacitinib and Adalimumab on Residual Pain Among Patients with Psoriatic Arthritis Whose Inflammation Was Attenuated After Three and Six Months of Treatment

1:00PM-3:00PM: Abstract Number: 2125

Effects of Treatment with Risankizumab on Minimal Disease Activity and Disease Activity in Psoriatic Arthritis: An Analysis of the KEEPsAKE-1 and -2 Trials

1:00PM-3:00PM: Abstract Number: 2145

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Trials

1:00PM-3:00PM: Abstract Number: 2146

Efficacy of Upadacitinib in Patients with Psoriatic Arthritis and Prior Exposure to Anti-TNF Therapy in the SELECT-PsA 2 Trial Through 2 Years

1:00PM-3:00PM: Abstract Number: 2135

Evaluation of Candidate Protein Biomarkers to Predict Treatment Response in Patients with Psoriatic Arthritis

1:00PM-3:00PM: Abstract Number: 2140

Exposure-Adjusted Incidence Rate for Adverse Events of Special Interest in Patients with Psoriatic Arthritis Treated with Apremilast

1:00PM-3:00PM: Abstract Number: 2110

Guselkumab Efficacy in Psoriatic Arthritis Assessed by Multi-domain Composite Indices: Data from the Phase 3b COSMOS Trial in a TNFi-IR Population

1:00PM-3:00PM: Abstract Number: 2127

Guselkumab Provides Continued Improvement in Key Domains of Psoriatic Arthritis Through 2 Years

1:00PM-3:00PM: Abstract Number: 2123

Hierarchical Ranking of Biologic Disease-Modifying Antirheumatic Drugs and Targeted Systemic Therapies for Psoriatic Arthritis: A Network Meta-analysis

1:00PM-3:00PM: Abstract Number: 2141

How Well Does Ultrasound-assessed Synovitis in Reduced Joint Sets Predict the Response to Secukinumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Conventional DMARDs? – Exploratory Results from a Phase 3b Study

1:00PM-3:00PM: Abstract Number: 2124

Immunological Differences Between PsA Patients Who Are Tumor Necrosis Factor Inhibitor-Naïve and Who Have Inadequate Response to Tumor Necrosis Factor Inhibitors

1:00PM-3:00PM: Abstract Number: 2137

Impact of Patient Characteristics, Including Sex, on the Efficacy of Upadacitinib Compared with Adalimumab in Patients with Psoriatic Arthritis

1:00PM-3:00PM: Abstract Number: 2126

Impact of Risankizumab on Enthesitis and Dactylitis: Integrated Analysis of the Phase 3, Randomized, Double-Blind KEEPsAKE 1 and 2 Trials

1:00PM-3:00PM: Abstract Number: 2113

Improvement in Key PsA Core Domains with Guselkumab Treatment in an Enriched Population of ACR20 Non-Responders at Week 24: Post Hoc Analysis of Two Phase 3 Studies

1:00PM-3:00PM: Abstract Number: 2151

Izokibep Demonstrates Clinically Relevant Efficacy Benefits on Enthesitis, Dactylitis and Nail Outcomes in Active PsA Patients: A 16-week Randomized, Placebo-controlled Trial

1:00PM-3:00PM: Abstract Number: 2144

JAK Inhibition Re-balances Gene Expression Profile of Circulating Immune Cells in Patients with Psoriatic Arthritis

1:00PM-3:00PM: Abstract Number: 2153

Key Differences Between US Rheumatologists’ and Dermatologists’ Management of Psoriatic Arthritis

1:00PM-3:00PM: Abstract Number: 2111

Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conducted in Biologic-naïve Patients with Active Psoriatic Arthritis

1:00PM-3:00PM: Abstract Number: 2121

Long-term Persistence of Second-line Biologics in Psoriatic Arthritis Patients with Prior TNF Inhibitor Exposure: A Nationwide Cohort Study from the French Health Insurance Database

1:00PM-3:00PM: Abstract Number: 2131

Minimal Disease Activity Response Patterns in Bio-Naïve Patients Treated with Guselkumab: A Machine Learning Analysis

1:00PM-3:00PM: Abstract Number: 2138

Real-world Persistence and Treatment Patterns in Psoriatic Arthritis Patients Treated with Anti-IL17 Therapy

1:00PM-3:00PM: Abstract Number: 2132

Safety of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor: As Assessed by Laboratory Parameters – Results from a Phase 2 Trial in Psoriatic Arthritis and 2 Phase 3 Trials in Psoriasis

1:00PM-3:00PM: Abstract Number: 2120

Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of 11 Phase 2/3 Clinical Studies in Psoriasis and Psoriatic Arthritis

1:00PM-3:00PM: Abstract Number: 2129

Serum Extracellular Matrix Biomarkers Identify Response to Guselkumab in Psoriatic Arthritis; Post-hoc Analysis from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years

1:00PM-3:00PM: Abstract Number: 2112

Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study

1:00PM-3:00PM: Abstract Number: 2142

Strong Correlation Between Short- vs Long-form Composite Measures of Psoriatic Arthritis Disease Activity in a TNFi-IR Population Treated with Guselkumab: Data from the Phase 3b COSMOS Trial

1:00PM-3:00PM: Abstract Number: 2139

Sustained Response to Guselkumab Regardless of Baseline Demographic, Disease, and Medication Characteristics in Patients with Active Psoriatic Arthritis and an Inadequate Response to TNF Inhibitors: Results from a Phase 3b Trial

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].